Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will host an Investor Day in New York City on Wednesday, June 17, 2026, beginning at 2:00 PM ET, with virtual access and a live webcast. Senior leadership and retinal disease key opinion leaders will participate. A replay will be archived for at least 30 days.

News Market Reaction – OCUL

+3.65%

6 alerts

+3.65% Session close to close

$2.13B Market Cap

0.0x Rel. Volume

In the Apr 22 session, OCUL gained 3.65%, reflecting a moderate positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026

BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on Wednesday, June 17, 2026, in New York City. Click here to register for the live event, with virtual access available, which will begin at 2:00 PM ET.

The Investor Day will include participation from Ocular Therapeutix senior leadership and prominent retinal disease key opinion leaders. Additional details will be provided in advance of the event.

A live webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website. A replay of the webcast will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When is Ocular Therapeutix's Investor Day and how can I attend (OCUL)?

The Investor Day is on June 17, 2026 at 2:00 PM ET, with in-person and virtual access. According to Ocular Therapeutix, registration is required for the live event and a webcast will be available for remote attendees.

Will Ocular Therapeutix (OCUL) provide a webcast and replay for the June 17 event?

Yes, a live webcast will be available and a replay archived for at least 30 days. According to Ocular Therapeutix, the webcast will be posted in the Events and Presentations section of the company's website.

Who will present at Ocular Therapeutix's Investor Day on June 17, 2026 (OCUL)?

Senior leadership and prominent retinal disease key opinion leaders will participate in presentations. According to Ocular Therapeutix, the program will include company executives alongside external retinal experts to discuss strategy and developments.

Where is Ocular Therapeutix holding the Investor Day and is it open to investors (OCUL)?

The event will be held in New York City and is accessible virtually for remote investors. According to Ocular Therapeutix, investors can register to attend in person or view the live webcast online.

How long will the Ocular Therapeutix (OCUL) webcast replay remain available after the Investor Day?

The replay will be archived for at least 30 days following the presentation. According to Ocular Therapeutix, viewers can access the archived webcast in the Events and Presentations section of the company website during that period.

Where can I register for Ocular Therapeutix's Investor Day on June 17, 2026 (OCUL)?

Registration is available through the company's investor event registration link. According to Ocular Therapeutix, interested participants should register in advance to secure virtual or in-person access to the June 17 Investor Day.